[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-cns-lymphoma-pcnsl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-cns-lymphoma-pcnsl":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100587689","phase-2-study-of-epcoritamab-in-rr-primary-diffuse-large-b-cell-lymphoma-of-the-cns-treated-with-lenalidomide-and-rituximab-100587689",false,"NCT06931652","Study of Epcoritamab in R\u002FR Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab","A Phase 2 Study Evaluating Epcoritamab in Subjects With Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab","E-REVRI","Inclusion Criteria:\n\n1. Subject (or their legally acceptable representative\u002Ftrusted person) who understand and voluntarily signs and dates an informed consent form prior to any study-specific assessments\u002Fprocedures being conducted.\n2. Subject ≥ 18 years old at the time of signing the informed consent form (ICF)\n3. Confirmed histology of primary diffuse large B-cell lymphoma of the CNS (according to the 2022 WHO classification) or confirmed cytology of primary vitreoretinal diffuse large B-cell lymphoma, with CD20 positivity in immunohistochemical staining or flow cytometry at any point in the disease history.\n4. Subjects with relapsed or refractory (R\u002FR) PCNSL or PVRL after at least one line of systemic therapy. Subject with R\u002FR PCNSL must have previously received at least high dose methotrexate. Subject with R\u002FR PVRL must have received either intravenous high dose methotrexate or intraocular methotrexate (PVRL cohort). Subjects can have received radiotherapy or intensive chemotherapy with hematopoietic stem cell rescue as part of treatment of the PCNSL or PVRL.\n5. ECOG performance status 0 to 2.\n6. Estimated minimum life expectancy of ≥ 2 months.\n7. R\u002FR PCNSL subjects with evaluable disease on brain MRI.\n8. Able to swallow capsules (stomach tube not allowed)\n9. Adequate hematopoietic function:\n\n   * Absolute neutrophil count of ≥ 1.0 G\u002FL without G-CSF support for at least 7 days before screening\n   * Platelet count of ≥ 50 G\u002FL without platelet transfusion within 7 days before screening\n   * Hemoglobin ≥ 8.0 g\u002FdL without RBC transfusion within 7 days before screening\n10. Adequate renal function: calculated by Cockcroft-Gault equation creatinine clearance \\> 40 ml\u002Fmin. Subjects with calculated creatinine clearance \\> 40 and \\\u003C 60ml\u002Fmin lenalidomide dose will be adjusted.\n11. Adequate liver function: Serum total bilirubin level ≤ 2.0 mg\u002Fdl \\[34 µmol\u002FL\\] (unless bilirubin rise is due to Gilbert's syndrome) and serum transaminases (AST or ALT) ≤ 3 upper normal limits.\n12. Able to understand teratogenic risks of the treatment (Lenalidomide).\n13. Women of childbearing potential (WOCBP) should agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study treatment, 2) while participating in the study, 3) dose interruptions, and 4) for at least 12 months after the final dose of rituximab, or for at least 12 months after the final dose of epcoritamab, or for at least 28 days after the final dose of lenalidomide . WOCBP should also agree to abstain from breastfeeding during study participation and for at least 4 months after discontinuation of all study treatments.\n14. WOCBP should have a negative serum (beta-hCG) pregnancy test at screening and a negative serum or urine pregnancy test before treatment administration on Day 1 of every cycle.\n15. Women should agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire study, until 12 months after the last administration of study treatment.\n16. Man who is sexually active with a female of reproductive potential and has not had a vasectomy should agree to use a highly effective \u002F an acceptable method of birth control (ie, condom) and must agree not to donate sperm, until 28 days after the final dose of lenalidomide and\u002For until 12 months after the final dose of epcoritamab and rituximab.\n17. Subject covered by any social security system (France).\n18. Subject (or their legally acceptable representative\u002Ftrusted person) who understands and speaks one of the country official languages unless local regulation authorizes independent translators.\n\nExclusion criteria:\n\nSubject who meets any of the following criteria should be excluded from enrollment in the study:\n\n1. T-cell lymphoma.\n2. Cerebral localization of a systemic lymphoma.\n3. Prior history of organ transplantation or other cause of severe immunodeficiency.\n4. Known Human Immunodeficiency Virus (HIV) or Positive HTLV1 serology.\n5. Active Hepatitis B Virus (HBV) infection (DNA PCR-positive) or active hepatitis C Virus (HCV) infection (RNA PCR-positive). Subjects with evidence of prior HBV infection but who are PCR-negative are permitted in the study but should receive prophylactic antiviral therapy. Subjects who received treatment for HCV infection that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable.\n6. Persistent SARS-CoV-2 infection. Subjects who have had or currently have a SARS-CoV-2 infection must demonstrate symptom resolution and provide a negative nasopharyngeal PCR test at time of inclusion. Both of these requirements must be met for the subject to be considered clear of the virus.\n7. Impossibility to follow the calendar of exams because of geographic, social, or psychological reasons.\n8. Active malignancy other than the one treated in this Study. Prior history of malignancies (other than inclusion diagnosis) unless the subject has been free of the disease for ≥ 2 years. However, subjects with the following history\u002Fconcurrent conditions are allowed:\n\n   1. Non-invasive basal cell or epidermoid carcinoma\n   2. In situ Carcinoma of the cervix\n   3. In situ Carcinoma of the breast\n   4. Non-invasive, superficial bladder cancer\n   5. Incidental histologic finding of prostate cancer (T1a or T1b) using the tumor, nodes, metastasis \\[TNM\\] clinical staging system\n   6. Any curable cancer with a complete response of \\>2 years duration\n9. Known or suspected hypersensitivity to the active substance or to any of the excipients.\n10. Any previous treatment with CAR-T therapy within 30 days prior to enrollment.\n11. Receiving immunosuppressive therapy, including more than the equivalent of 20 mg of prednisolone daily, unless for control of lymphoma or intermittent prophylaxis\u002Ftreatment of allergic reactions.\n12. Any previous treatment with a bispecific antibody targeting CD3 and CD20 and\u002For with lenalidomide, regardless of the time and duration.\n13. Seizure disorder requiring anti-epileptic therapy unless related to lymphoma.\n14. Vaccination with live, attenuated vaccines within 28 days prior of enrollment (except severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine). Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Experimental and\u002For non-authorized SARS-CoV-2 vaccinations are not allowed.\n15. Use of any standard or experimental anti-cancer drug therapy within 28 days of the start (Day 1) of study treatment.\n16. Major surgery within 4 weeks prior to enrollment\n17. Clinically significant cardiovascular disease, including:\n\n    1. Myocardial infarction within 1 year prior to enrollment, or unstable or uncontrol disease\u002Fcondition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association Class III-IV) cardiac arrhythmia (CTCAE Version 5.0 Grade 2 or higher), or clinically significant ECG abnormalities.\n    2. Stroke within 6 months prior to enrollment.\n18. Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) \\>470 msec.\n19. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection requiring systemic treatment at time of enrollment.\n20. Contraindication to all uric acid lowering agents.\n21. Clinically significant liver disease, including active hepatitis, current alcohol abuse, or cirrhosis.\n22. Active tuberculosis or history of treatment for active tuberculosis within the past 12 months.\n23. Receiving immunostimulatory agent.\n24. Prior allogeneic hematopoietic stem cell transplantation.\n25. Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with participation in this clinical study (according to the investigator's decision).\n26. Subject deprived of his\u002Fher liberty by a judicial or administrative decision.\n27. Subject hospitalized without consent.\n28. Adult subject under legal protection.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this phase 2 study is to evaluate the efficacy and safety of epcoritamab in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and lenalidomide.",[27],"Primary CNS Lymphoma (PCNSL)",[29,30,31,32,27],"primary CNS lymphoma","treatment for primary CNS lymphoma","epcoritamab treatment","rituximab and lenalidomide treatment","RECRUITING","2026-06-12",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":37},"2025-09-22",{"date":41,"type":21},"2030-01",{"name":43,"class":44},"The Lymphoma Academic Research Organisation","OTHER",13,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100597756","phase-2-anbalcabtagene-autoleucel-in-relapsedrefractory-cns-lymphoma-100597756","NCT07062627","Anbalcabtagene Autoleucel in Relapsed\u002FRefractory CNS Lymphoma","A Pilot Study of Anbalcabtagene Autoleucel in Patients With Relapsed\u002FRefractory Primary or Secondary Central Nervous System Lymphoma","Inclusion Criteria:\n\n1. Individuals aged 19 years or older who voluntarily agree to participate in this clinical study and provide written consent.\n2. Patients with recurrent\u002Frefractory B-cell lymphoma confirmed histologically according to the 2017 WHO classification, and who meet one of the following conditions:\n\n   Primary central nervous system lymphoma (PCNSL) of the DLBCL subtype Secondary central nervous system involvement of DLBCL with no involvement outside the central nervous system\n3. Patients who failed treatment with a previous regimen that included high-dose methotrexate or patients intolerant to high-dose methotrexate.\n4. Patients who agree to provide tumor tissue. If a stored tumor tissue sample is available, it can be submitted only if it was collected within 6 months prior to participation in the clinical study and if no systemic anticancer treatment was administered after collection. If the stored tissue sample does not meet these conditions, tumor tissue must be obtained through a core needle biopsy or excisional biopsy during the screening period. If the investigator deems the biopsy to be medically unsafe for the patient, the decision on whether to enroll the patient in the clinical study can be made in consultation with the patient's clinical physician.\n5. Individuals with an ECOG performance status score of 2 or lower at the time of screening.\n6. Individuals with appropriate renal and liver function confirmed by laboratory test results:\n\n   Total Bilirubin ≤2.0 mg\u002FdL (for individuals with Gilbert-Meulengracht syndrome: total bilirubin ≤3.0 × upper limit of normal (ULN), direct bilirubin ≤1.5 x ULN) Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 × ULN (if liver metastasis is confirmed: AST, ALT ≤5 × ULN) Serum creatinine ≤1.5 x ULN Estimated glomerular filtration rate (eGFR)\\* ≥60 mL\u002Fmin\u002F1.73 m²\n\n   \\*MDRD-GFR (mL\u002Fmin\u002F1.73 m²) = 186 × (serum creatinine)-1.154 × (age)-0.203 (× 0.742 for females)\n7. Individuals with appropriate hematologic function confirmed within 2 weeks prior to screening without transfusion, based on the following criteria:\n\n   Hemoglobin \\>8.0 g\u002FdL Absolute neutrophil count (ANC) \\>1,000\u002FμL Absolute lymphocyte count (ALC) ≥300\u002FμL Platelets ≥50,000\u002FμL\n8. Individuals who are hemodynamically stable at the time of screening, have no signs of pericardial effusion, and have a left ventricular ejection fraction of 50% or higher based on an echocardiogram (ECHO) or multigated acquisition (MUGA) scan.\n9. Individuals from whom adequate non-mobilized cells for Anbal-cel manufacturing can be collected through leukapheresis.\n10. Individuals with an expected survival of 12 weeks or longer.\n11. Individuals who agree to comply with the scheduled site visits, examination schedules, and assessments as per the protocol during the course of the clinical study, including primary and secondary follow-up visits.\n12. Women of childbearing potential and men who agree to use appropriate contraception\\* for at least 12 months after Anbal-cel administration until Anbal-cel is no longer detected in PCR tests. \\*Hormonal contraception, intrauterine system implants, dual barrier methods (simultaneous use of a diaphragm or cervical cap with a condom and spermicide), sterilization procedures (e.g., vasectomy, bilateral tubal ligation), etc.\n\nExclusion Criteria:\n\n1. Individuals with a history of allogeneic hematopoietic stem cell transplantation.\n2. Individuals with the following medical history:\n\n   * History of other malignancies, except B-cell non-Hodgkin lymphoma, within 3 years prior to screening (however, individuals with a history of basal cell carcinoma, squamous cell carcinoma of the skin, localized prostate cancer, papillary thyroid cancer, cervical carcinoma in situ, or early-stage gastric cancer may participate if the investigator considers them to be fully cured after successful treatment, even if 3 years have not passed).\n   * History of unstable angina and\u002For myocardial infarction within 12 months prior to screening.\n   * History of thromboembolism, pulmonary embolism, or bleeding diatheses within 6 months prior to screening.\n   * History of hypoxia, clinically significant pleural effusion, or abnormal electrocardiogram findings within 6 months prior to screening.\n3. Individuals with the following conditions at the time of screening:\n\n   * Known positive for human immunodeficiency virus (HIV).\n   * Active neurological autoimmune or inflammatory diseases (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis).\n   * Recurrent or symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response despite treatment in the 3 months prior to screening.\n4. Individuals whose disease is rapidly progressing, as determined by the investigator.\n5. Individuals who have undergone major surgery requiring general anesthesia or respiratory support within 4 weeks prior to screening (however, video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery is permissible if conducted within 2 weeks).\n6. Individuals with severe infections requiring the administration of antibiotics, antifungals, or antivirals at the time of screening or with uncontrolled active infections.\n7. Individuals who have received or been exposed to other investigational drugs or devices within 4 weeks prior to screening.\n8. Pregnant or breastfeeding women.\n9. Individuals with a hypersensitivity to the ingredients of the investigational drug.","19 Years",{"count":55,"type":21},12,[24],"This clinical study aims to evaluate the tolerability, safety, and efficacy of Anbal-cel in patients with recurrent or refractory PCNSL or SCNSL.\n\nSubjects who have provided written consent and meet the inclusion and exclusion criteria through screening evaluations will undergo leukapheresis (LP) for Anbal-cel manufacturing. Subjects whose collected nucleated cells are confirmed suitable for Anbal-cel production will be enrolled in the clinical study.\n\nPrior to Anbal-cel administration, lymphodepletion therapy will be performed and must be completed at least 2 days before Anbal-cel administration. Anbal-cel will be administered to subjects who meet the inclusion and exclusion criteria for Anbal-cel administration.\n\nStudy subjects will be hospitalized for a minimum of 7 days to closely monitor adverse events and receive prompt necessary treatment after Anbal-cel administration. All study subjects will undergo primary visit evaluations for 12 months following Anbal-cel administration.\n\nSubjects who discontinue primary visit evaluations before the 12-month visit will undergo an end of study 1 (EOS1) visit for safety observation. For subjects whose primary visit evaluations end before the 12-month visit due to disease progression (PD), withdrawal of consent for primary visit evaluations, or subsequent anti-cancer therapy, secondary follow-up visits will be conducted from the EOS1 visit to the 12-month time point (EOS2). The timing of the first secondary follow-up visit will be determined based on when the subject's primary visit evaluation was discontinued.\n\nA separate long-term follow-up study is planned to monitor long-term safety, including delayed adverse events (AEs), in subjects who received Anbal-cel. In this long-term follow-up study, each subject will be followed for 15 years from the date of Anbal-cel administration. All specific details, including the visit schedule and examination items for the long-term follow-up study, will be described in a separate protocol.",[27,59],"Diffuse Large B Cell Lymphoma (DLBCL)",[61,62,63],"lymphoma","CAR-T","Anbalcabtagene autoleucel","2025-12-15",{"date":66,"type":37},"2025-12-17",{"date":68,"type":37},"2025-11-12",{"date":70,"type":21},"2027-12-31",{"name":72,"class":44},"Hyungwoo Cho",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":100},"100572744","phase-2-nb02-poseltinib-combined-rituximab-and-lenalidomide-in-rr-pcnsl-100572744","NCT06737250","NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R\u002FR PCNSL","Open, Single Arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) Combined with Rituximab and Lenalidomide As a Salvage Therapy for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma","POTENTIAL-P","Inclusion Criteria:\n\n1. A patient who voluntarily decided to participate and provided written consent after receiving an explanation of this clinical trial and the characteristics of the investigational drug.\n2. Adults aged 19 years or older and 80 years or younger.\n3. Patients diagnosed histopathologically with CD20-positive primary central nervous system lymphoma (PCNSL).\n4. Patients with confirmed disease progression or treatment resistance after remission induction therapy, radiotherapy, or autologous transplantation, with no more than two prior systemic treatments and no more than one prior radiotherapy treatment (preconditioning and transplantation for hematopoietic stem cells are counted as one systemic treatment; radiotherapy, regardless of fractionation or dose, including concurrent chemoradiotherapy, is counted as one treatment).\n5. Patients with measurable lesions identified by gadolinium-enhanced brain MRI (CT may be used if MRI is contraindicated).\n6. Patients with an ECOG Performance Status (PS) score of 2 or less.\n7. Patients who agree to comply with the Pregnancy Prevention Plan (PPP) for lenalidomide.\n8. Patients with an expected survival of at least 3 months, as judged by the investigator.\n\nExclusion Criteria:\n\n1. Patients newly diagnosed with primary central nervous system lymphoma (PCNSL).\n2. Patients with ocular lymphoma without brain lesions.\n3. Patients with metastatic CNS lymphoma involving organs outside the central nervous system, except th eeyes and cerebrospinal fluid (if systemic disease is present: Secondary CNS lymphoma).\n4. Patients whose screening laboratory test results meet the following criteria (⁕ corrected after transfusion or use of hematopoietic growth factors are acceptable):\n\n(1) Absolute neutrophil count \\\u003C1,000\u002FμL (at least 2 weeks after G-CSF administration).\n\n(2) Platelet count \\\u003C75,000\u002FμL (at least 1 week after platelet transfusion). (3) Hemoglobin \\\u003C9.0 g\u002FdL (at least 2 weeks after red blood cell transfusion). (4) Serum calcium \\>12.0 mg\u002FdL. (5) Serum creatinine \\>1.5 x the upper normal limit (UNL) or creatinine clearance \\\u003C60 mL\u002Fmin (based on the Cockcroft-Gault formula).\n\n(6) Alanine aminotransferase (ALT) \\>3 × UNL. (7) Aspartate aminotransferase (AST) \\>3 × UNL. (8) Total bilirubin \\>1.5 × UNL (Gilbert syndrome: up to 3 × UNL).\n\n* Patients with cardiovascular, hepatic, renal, neurological, immune, infectious, or psychiatric disorders that could affect safety, trial evaluation, or protocol compliance (e.g., regular visits).\n\n  5\\. The following heart conditions:\n  1. Symptomatic or uncontrolled angina and congestive heart failure.\n  2. Arrhythmias requiring medication (controlled cases with medication are allowed).\n  3. Clinically significant myocardial infarction within 6 months before trial participation.\n\n  6\\. History of thrombosis or embolism within 6 months before screening.\n\n  7\\. Gastrointestinal bleeding above Grade 2 according to CTCAE within 6 months before screening.\n\n  8\\. Ongoing infection above Grade 2 according to CTCAE at the time of screening.\n\n  9\\. Severe hepatic impairment (e.g., cirrhosis), chronic hepatitis with HBV reactivation.\n  * Patients with HBsAg (-) and HBcAb (-), or HBsAg (-) and HBcAb (+) with undetectable HBV DNA, can participate. Prophylactic antiviral therapy and HBV DNA monitoring (every 3-4 weeks) are required for HBcAb (+) cases with undetectable HBV DNA.\n\n    10\\. Uncontrolled hepatitis C virus (HCV) infection.\n  * Patients with negative HCV antibodies or undetectable HCV RNA can participate with HCV RNA monitoring (every 1 cycle).\n\n    11\\. HIV infection. Patients with negative HIV antibodies or antigen-negative despite HIV antibody positivity can participate.\n\n    12\\. Severe renal impairment requiring hemodialysis or hemofiltration at screening.\n\n    13\\. Known immunodeficiency disorders.\n\n    14\\. Known autoimmune diseases (e.g., multiple sclerosis, acute disseminated encephalomyelitis, rheumatoid arthritis).\n\n    15\\. History of severe cutaneous adverse reactions (SCARs), including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), or acute generalized exanthematous pustulosis (AGEP).\n\n    16\\. History of malignancies other than the target disease, except:\n    1. No treatment for malignancy and disease-free for at least 5 years before screening.\n    2. Completely cured with no evidence of recurrence for malignancies within 5 years if surgically treated (e.g., Stage I\u002FII papillary or follicular thyroid cancer, basal cell\u002Fsquamous cell carcinoma, cervical dysplasia or carcinoma in situ, early-stage stomach or colorectal cancer).\n\n    17\\. Patients suspected of moderate dementia (K-MMSE-2 score ≤17).\n\n    18\\. Patients unable to take oral medication.\n\n    19\\. Hypersensitivity to study drugs (rituximab, lenalidomide, poseltinib) or excipients.\n\n    20\\. Prior use of lenalidomide, poseltinib, or other BTK inhibitors.\n\n    21\\. Genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n\n    22\\. Women who are pregnant or breastfeeding.\n\n    23\\. Women of childbearing potential⁕ and male participants with female partners of childbearing potential who do not agree to use two reliable contraceptive methods at least 28 days before administration of the investigational drug, during the trial, during temporary discontinuation, and for 12 months after the last administration. (Complete abstinence from heterosexual intercourse is an exception.)\n* Women not of childbearing potential include those who have undergone hysterectomy or bilateral oophorectomy, or those in natural menopause for at least 24 consecutive months for non-disease reasons.\n\n  24\\. Male participants who do not agree to:\n  1. Use condoms during the study, even after vasectomy, during temporary discontinuation, and for 12 months after the last administration.\n  2. Avoid sperm\u002Fsemen donation for 12 months after the study.\n  3. Immediately inform investigators if their partner becomes pregnant during the study or within 3 months after the study.\n\n  25\\. Patients with a history of substance abuse, medical, psychiatric, or social conditions that could interfere with trial participation or results.\n\n  26\\. Patients unable to understand or comply with trial instructions or with a history of poor adherence to medical treatments.","80 Years",{"count":84,"type":21},33,[24],"An Open, Single treatment arm, Multi-center, Prospective, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) combined with Rituximab and Lenalidomide as a Salvage Therapy for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma",[27],[89,90],"Refractory","Relapsed","2024-12-11",{"date":93,"type":37},"2024-12-17",{"date":95,"type":37},"2024-11-25",{"date":70,"type":21},{"name":98,"class":99},"NOBO Medicine","INDUSTRY",10]